![]() |
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CELLULAR AND MOLECULAR
Department of Pharmaceutical/Medicinal Chemistry II, Institute of Pharmacy, University of Regensburg, Regensburg, Germany (H.P., P.G., A.K., S.D., A.B.); and Department of Pharmacology and Toxicology, Institute of Pharmacy, University of Regensburg, Regensburg, Germany (R.S.)
Previous studies revealed pharmacological differences between human and guinea pig histamine H2 receptors (H2Rs) with respect to the interaction with guanidine-type agonists. Because H2R species variants are structurally very similar, comparative studies are suited to relate different properties of H2R species isoforms to few molecular determinants. Therefore, we systematically compared H2Rs of human (h), guinea pig (gp), rat (r), and canine (c). Fusion proteins of hH2R, gpH2R, rH2R, and cH2R, respectively, and the short splice variant of Gs
, Gs
S, were expressed in Sf9 insect cells. In the membrane steady-state GTPase activity assay, cH2R-Gs
S but neither gpH2R-Gs
S nor rH2R-Gs
S showed the hallmarks of increased constitutive activity compared with hH2R-Gs
S, i.e., increased efficacies of partial agonists, increased potencies of agonists with the extent of potency increase being correlated with the corresponding efficacies at hH2R-Gs
S, increased inverse agonist efficacies, and decreased potencies of antagonists. Furthermore, in membranes expressing nonfused H2Rs without or together with mammalian Gs
S or H2R-Gs
fusion proteins, the highest basal and GTP-dependent increases in adenylyl cyclase activity were observed for cH2R. An example of ligand selectivity is given by metiamide, acting as an inverse agonist at hH2R-Gs
S, gpH2R-Gs
S, and rH2R-Gs
S in the GTPase assay in contrast to being a weak partial agonist with decreased potency at cH2R-Gs
S. In conclusion, the cH2R exhibits increased constitutive activity compared with hH2R, gpH2R, and rH2R, and there is evidence for ligand-specific conformations in H2R species isoforms.
Address correspondence to: Dr. Roland Seifert, Department of Pharmacology and Toxicology, University of Regensburg, Universitätsstraße 31, D-93053 Regensburg, Germany. E-mail: roland.seifert{at}chemie.uni-regensburg.de